These 3 Marijuana Stocks Have Minted Our Readers Gains Up to 990% - and Counting

Marijuana stocksMarijuana stocks are in high demand now that over 29 states have legalized marijuana in some form. As more states adopt legalization, opportunities for marijuana entrepreneurs - and pot stock investors - abound.

2016 North American sales for legal marijuana topped $6.7 billion; by 2020, analysts expect sales to climb to $21.8 billion.

That's a 225% increase in sales in just four years.

But in order to take advantage of the trend and be a successful pot stock investor, you need to be able to separate the frontrunners from the duds.

That's why we're showing you how to easily find the right pot stocks to buy (and how to buy them) for the biggest profit potential in 2017.

You see, now is a better time than ever.

Along with many other equities, cannabis and related stocks have enjoyed triple-digit gains since the post-election "Trump Bump."

However, the market has steadied from its post-election rally, creating attractive entry points.

Here's a list of three marijuana stocks that have made our readers rich, plus the latest pot stock play from our renowned marijuana expert, Michael A. Robinson...

Best Marijuana Stocks No. 3: Lexaria Bioscience Corp. (OTCMKTS: LXRP)

Lexaria Bioscience Corp. provides edibles infused with hemp oil to all 50 states. In the long term, Lexaria plans to launch a hemp oil-infused protein bar as well as teas, coffees, and related goods.

We first told you about Lexaria Bioscience back in November 2016, when it was trading at just $0.24 per share.

Now, the small cannabis company is trading at $0.36 per share - a 50% increase.

And it's poised to keep growing...

"[Lexaria's] technology has proven to be a potential game changer in the cannabinoid-based pharmaceuticals market, an industry that's on course to grow to $50 billion by 2029, per data aggregated by Statista," according to Biotech Investing News on Aug. 18.

Best Marijuana Stocks No. 2: Insys Therapeutics Inc. (Nasdaq GM: INSY)

Insys Therapeutics stock gave Money Morning readers nearly 26% gains in just 12 trading sessions after we recommended buying the stock on May 14.

In fact, we told you about this company before the U.S. Food and Drug Administration (FDA) even gave the company final approval for its new drug on May 24.

And that approval is just the beginning of big profits for our readers...

Syndros - the company's blockbuster new drug - is positioned to be a leading player in a very large market.

Special Report: Cannabis Is the Gold Rush of the 21st Century - 30 Stocks to Invest in Now. Read more...

Syndros is a cannabinoid-derived drug that helps fight nausea and pain.

The National Cancer Institute reports that 15 million U.S. patients were treated for cancer in 2014, and 80% of those patients experienced nausea and vomiting from chemotherapy.

And in 2015, Transparency Market Research reported that the pain market was worth over $60 billion. By 2024, it is expected to hit $83 billion. That's more than a 33% increase.

That means Insys is well-positioned to capitalize on this $83 billion market with its latest drug.

This next pot stock is our biggest winner to date, with a 990% return since we recommended it to readers four years ago. Not only that, it's the absolute best pot stock to buy for risk-averse investors...

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

Best Marijuana Stocks No. 1: GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH)

While there's no such thing as a 100% safe investment, we have uncovered one of the best marijuana stocks to own for risk-averse investors.

We're talking about GW Pharmaceuticals Plc.

GW Pharmaceuticals is a biopharmaceutical company that specializes in cannabis-derived pain management drugs.

Our Readers Rave About Michael A. Robinson

"Just a note to let you know, I read hundreds of emails a day, many from news sources like Huffington Post, and dozens of investment newsletters, some trying to sell me a subscription and some I subscribe to. None of them provide me the forward thinking and outstanding reporting on the future of science, industry, and humanity as does your reporting. I love it and hope you never stop." ~ Jay C.

"We need more people like you on the planet - keep up the incredible research you are doing - make it happen. My glass is always half full." ~ Calvin M.

"Your column is absolutely fascinating. It makes me dream and feel hope." ~ Elizabeth R.

Not only has the company helped millions of people suffering from chronic pain, but it's also made our investors very, very rich.

In fact, since the summer of 2013, its share price has risen from about $9 per share to today's $99 price. That's a 992.37% increase.

And we're looking at even more gains ahead for the next year, as the company is set to receive approval to launch a revolutionary cannabis-based medicine, Epidiolex.

Epidiolex is thought to help children with childhood epilepsy and Dravet syndrome, a rare genetic epileptic dysfunction. It's currently in its phase 3 trials - arguably the most important stage of a drug's approval.

You see, phase 3 trials judge the efficacy and side effects of a drug before it is approved. And Money Morning Director of Technology & Venture Capital Research Michael A. Robinson is optimistic. In fact, Michael believes Epidiolex will one day be distributed to a much larger market than originally intended.

Michael is our renowned pot stock expert and one of our most prominent and respected investing "gurus" here at Money Morning - and for good reason.

He is one of the top financial analysts working today. Make no mistake: Michael's ideas are completely his own.

He's been a board member for a Silicon Valley venture capital firm and a senior advisor to 12 high-tech startups.

He's also a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style.

His research is world class, too. The Oakland Tribune, Detroit News, The San Francisco Examiner, The Kansas City Times, Wealth Magazine, and American Banker have all published his reporting. He's even appeared on Larry King's syndicated radio show and is a regular guest on CNBC's "The Rundown" and FOX Business Network's "Cavuto: Coast to Coast."

And he believes mega profits are on the horizon for GW Pharma.

"Children won't end up being Epidiolex's only focus. After all, chronic pain affects everyone, especially seniors - the drug industry's most important (and growing) market," said Michael.

By 2030, more than 20% of U.S. residents are projected to be aged 65 and over, compared with 13% in 2010 and 9.8% in 1970.

"We're at the beginning of a sea of change in how we treat chronic pain, shifting from opioid-based medications to cannabis-based ones," said Michael.

"And with first-mover advantage, we're in the perfect spot to profit."

Get Michael's Best Stock Picks Now

A new, earth-shattering government announcement could completely change the legalization of marijuana - forever.

In fact, thanks to this historic legislation, tiny pot stocks trading for under $5 are getting set to double, triple, or quadruple.

In an exclusive interview with Money Morning, Michael shares all the good news - including details on five tiny weed stocks that could potentially turn a small stake into $100,000.

Continue reading...

For more marijuana industry updates, follow Money Morning on Twitter @moneymorningFacebook, and LinkedIn.